Lenvima

Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
New Products: FDA approves combination regimen to treat advanced RCCOther products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more.
RCC: Two approvals expand options for TKI-refractory patientsFDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.
New treatment for kidney cancer gets OKFDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.
Product Preview: Agreement reached for phase III clinical trial of bladder Ca agentIn this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
FDA approves Lenvima for a type of thyroid cancerFDA has approved lenvatinib (Lenvima, Eisai) for the treatment of progressive, differentiated thyroid cancer.
FDA drug approvals-February 2015FDA actions in brief, priority review, breakthrough designations, orphan drug designations